Evidence map›Paper›PMID 40242170›Full record

ArticleGastro hep advances2025

Usability of a Mobile Point-of-Care App for the Index of Severity for Eosinophilic Esophagitis.

Evan S Dellon, Glenn T Furuta, Nick Tomeo, Anya Karavanov, Zoe Smernoff, Joy Harrington, Seema S Aceves

Abstract read
In one paragraph

Article in Gastro hep advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Evan S DellonCenter for Esophageal Diseases and Swallowing, University of North Carolina School of Medicine, Chapel Hill, North Carolina.
Glenn T FurutaGastrointestinal Eosinophilic Diseases Program and Mucosal Inflammation Program, Department of Pediatrics, University of Colorado School of Medicine, Digestive Health Institute, Children's Hospital Colorado, Aurora, Colorado.
Nick TomeoAmerican Gastroenterological Association, Bethesda, Maryland.
Anya KaravanovKnighten Health, Bethesda, Maryland.
Zoe SmernoffKnighten Health, Bethesda, Maryland.
Joy HarringtonKnighten Health, Bethesda, Maryland.
Seema S AcevesDivision of Allergy, Immunology, University of California San Diego and Rady Children's Hospital, San Diego, California.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: A new application (app) allows the Index of Severity for EoE (I-SEE) to be used at the point of care. We aimed to perform usability testing of the I-SEE mobile app and identify areas for improvement. Methods: We recruited 60 practitioners (20 adult and 20 pediatric gastroenterologists; 20 allergists) to use I-SEE on ≥5 EoE patients seen in clinic and undergo interviews by trained qualitative researchers. The interview guide focused on overall user experience, user satisfaction, and desired improvements. It also explored potential perceived barriers to using the app and I-SEE. Results: Though I-SEE was new to most providers, they found it took only a few minutes to calculate the score. All interviewees either "agreed" (5%) or "strongly agreed" (95%) with the statement, "The app was easy to navigate," and almost all (95%) either "agreed" (42%) or "strongly agreed" (53%) with "The app's features and functionalities were intuitive and easy to understand". The large majority (85%) reported satisfaction with the app. Responses were similar for allergists, and adult and pediatric gastroenterologists. Areas of suggested improvement included updating design features, incorporation into electronic medical records, addressing if scoring for children and adults should be different, and clarifying clinical implications of I-SEE for management. Conclusion: The I-SEE app was user friendly and able to be completed rapidly in clinical practice. Interviewee feedback led to app updates to improve visualization and use. In the future, scoring for children should be confirmed and I-SEE should be validated by linking severity to treatment and monitoring recommendations.

Indexed as

AppAssessmentEosinophilic EsophagitisSeverity

Identifiers

PMID40242170
PMCPMC12001112

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.